MX2022014163A - Composiciones de polipeptido de fusion il-2 y metodos para fabricarlas y usarlas. - Google Patents
Composiciones de polipeptido de fusion il-2 y metodos para fabricarlas y usarlas.Info
- Publication number
- MX2022014163A MX2022014163A MX2022014163A MX2022014163A MX2022014163A MX 2022014163 A MX2022014163 A MX 2022014163A MX 2022014163 A MX2022014163 A MX 2022014163A MX 2022014163 A MX2022014163 A MX 2022014163A MX 2022014163 A MX2022014163 A MX 2022014163A
- Authority
- MX
- Mexico
- Prior art keywords
- making
- methods
- same
- fusion polypeptide
- polypeptide compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 101150083678 IL2 gene Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022860P | 2020-05-11 | 2020-05-11 | |
| PCT/US2021/031616 WO2021231319A1 (en) | 2020-05-11 | 2021-05-10 | Il-2 fusion polypeptide compositions and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014163A true MX2022014163A (es) | 2023-02-22 |
Family
ID=78524880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014163A MX2022014163A (es) | 2020-05-11 | 2021-05-10 | Composiciones de polipeptido de fusion il-2 y metodos para fabricarlas y usarlas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395325A1 (enExample) |
| EP (1) | EP4149514A4 (enExample) |
| JP (1) | JP2023526024A (enExample) |
| KR (1) | KR20230008759A (enExample) |
| CN (1) | CN115867307A (enExample) |
| AU (1) | AU2021269585A1 (enExample) |
| BR (1) | BR112022022869A2 (enExample) |
| CA (1) | CA3172874A1 (enExample) |
| IL (1) | IL298064A (enExample) |
| MX (1) | MX2022014163A (enExample) |
| TW (1) | TW202207971A (enExample) |
| WO (1) | WO2021231319A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156897B2 (en) * | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| AU2015236340B2 (en) * | 2014-03-24 | 2020-02-06 | Bioverativ Therapeutics Inc. | Lyophilized factor IX formulations |
| AU2015364396B2 (en) * | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| UY37726A (es) * | 2017-05-05 | 2018-11-30 | Amgen Inc | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados |
| WO2019019998A1 (zh) * | 2017-07-25 | 2019-01-31 | 江苏恒瑞医药股份有限公司 | 一种il-15蛋白复合物药物组合物及其用途 |
| BR112022007158A2 (pt) * | 2019-10-18 | 2022-07-05 | Alkermes Pharma Ireland Ltd | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico |
-
2021
- 2021-05-10 US US17/315,974 patent/US20210395325A1/en not_active Abandoned
- 2021-05-10 BR BR112022022869A patent/BR112022022869A2/pt unknown
- 2021-05-10 IL IL298064A patent/IL298064A/en unknown
- 2021-05-10 CN CN202180040284.5A patent/CN115867307A/zh active Pending
- 2021-05-10 WO PCT/US2021/031616 patent/WO2021231319A1/en not_active Ceased
- 2021-05-10 JP JP2022568632A patent/JP2023526024A/ja active Pending
- 2021-05-10 CA CA3172874A patent/CA3172874A1/en active Pending
- 2021-05-10 EP EP21804274.5A patent/EP4149514A4/en active Pending
- 2021-05-10 AU AU2021269585A patent/AU2021269585A1/en not_active Abandoned
- 2021-05-10 KR KR1020227041366A patent/KR20230008759A/ko active Pending
- 2021-05-10 MX MX2022014163A patent/MX2022014163A/es unknown
- 2021-05-11 TW TW110116904A patent/TW202207971A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021231319A1 (en) | 2021-11-18 |
| BR112022022869A2 (pt) | 2023-01-31 |
| AU2021269585A1 (en) | 2022-12-15 |
| IL298064A (en) | 2023-01-01 |
| US20210395325A1 (en) | 2021-12-23 |
| EP4149514A4 (en) | 2024-06-26 |
| CN115867307A (zh) | 2023-03-28 |
| CA3172874A1 (en) | 2021-11-18 |
| JP2023526024A (ja) | 2023-06-20 |
| TW202207971A (zh) | 2022-03-01 |
| EP4149514A1 (en) | 2023-03-22 |
| KR20230008759A (ko) | 2023-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY202933A (en) | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | |
| IL290598A (en) | Modified interleukin 2 (il-2) polypeptides, conjugates and uses them | |
| WO2019191633A3 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| MX2023001595A (es) | Proteinas de fusion que comprenden proteinas de leche y composiciones de las mismas. | |
| CY1122494T1 (el) | Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων | |
| NZ756674A (en) | Albumin binding domain fusion proteins | |
| MX2020007389A (es) | Polipéptidos de unión al receptor de transferrina y usos de estos. | |
| CR20220530A (es) | CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 ß¿c Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO. | |
| WO2020008377A3 (en) | Ionic self-assembling peptides | |
| PH12023552771A1 (en) | Compositions comprising a variant polypeptide and uses thereof | |
| MX2019008549A (es) | Anticuerpos dirigidos a los huesos. | |
| ES2723774T3 (es) | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal | |
| WO2021188374A3 (en) | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides | |
| PH12022550326A1 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
| UY27439A1 (es) | Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj | |
| MX2021016117A (es) | Complejos peptidos-mhc. | |
| MX2022014164A (es) | Composiciones de polipeptido de fusion il-2 y metodos para fabricarlas y usarlas. | |
| MX2022014163A (es) | Composiciones de polipeptido de fusion il-2 y metodos para fabricarlas y usarlas. | |
| MX2023002439A (es) | Composiciones immunogénicas y usos de las mismas. | |
| MX2021012964A (es) | Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15. | |
| NZ787849A (en) | Composition for culturing natural killer cells and method for preparing natural killer cells by using same | |
| MX2022009134A (es) | Metodos de purificacion. | |
| MX2019009063A (es) | Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. | |
| EP4058468A4 (en) | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF | |
| PH12020551582A1 (en) | Lfa3 variants and compositions and uses thereof |